BOLD
Boundless Bio, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$26.44M
P/E Ratio
—
EPS
$-2.60
Beta
-0.26
52W High
$1.78
52W Low
$0.96
50-Day MA
$1.14
200-Day MA
$1.18
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Boundless Bio, Inc. Common Stock
Audentes Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing gene therapy products for patients living with serious and life-threatening rare diseases caused by single gene defects. The company is headquartered in San Francisco, California.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-62.30M |
| Operating Margin | 0.00% |
| Return on Equity | -46.70% |
| Return on Assets | -21.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.40 |
| Price-to-Book | 0.24 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $22.41M |
| Float | $16.36M |
| % Insiders | 11.38% |
| % Institutions | 51.21% |
Analyst Ratings
Consensus ($4.00 target)
2
HoldData last updated: 4/7/2026